Zhang Haijian, Liu Yidong, Xie Huyang, Fu Qiang, Liu Zheng, Zhu Yu, Xu Le, Zhang Weijuan, Yang Yuanfeng, Xu Jiejie
1 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
2 Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Jiangsu, China.
Tumour Biol. 2017 Feb;39(2):1010428317691417. doi: 10.1177/1010428317691417.
Beta-1,4-galactosyltransferase II is found to be associated with the alterations of tumor-related glycosylation. However, the clinical significance of beta-1,4-galactosyltransferase II in non-metastatic clear-cell renal cell carcinoma has not been reported up to now. Herein, our researches suggested that the expression level of beta-1,4-galactosyltransferase II was first found to be positively associated with tumor size, Fuhrman grade, lymphovascular invasion, rhabdoid differentiation, tumor necrosis and poor overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma, both in training set and validation set. Moreover, beta-1,4-galactosyltransferase II expression was identified as an independent adverse prognosticator for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Ultimately, prognostic accuracy of the nomogram integrating beta-1,4-galactosyltransferase II with other independent prognostic parameters was dramatically improved for overall survival and recurrence-free survival of patients with non-metastatic clear-cell renal cell carcinoma. Taken together, beta-1,4-galactosyltransferase II is a potential independent adverse prognostic factor for postoperative recurrence and survival, which could be developed as a useful biomarker for non-metastatic clear-cell renal cell carcinoma by a series of further independent and retrospective studies, so as to help the postsurgical management of clear-cell renal cell carcinoma patients.
β-1,4-半乳糖基转移酶II被发现与肿瘤相关糖基化的改变有关。然而，β-1,4-半乳糖基转移酶II在非转移性透明细胞肾细胞癌中的临床意义迄今尚未见报道。在此，我们的研究表明，首次发现β-1,4-半乳糖基转移酶II的表达水平与非转移性透明细胞肾细胞癌患者的肿瘤大小、Fuhrman分级、淋巴管浸润、横纹肌样分化、肿瘤坏死以及较差的总生存期和无复发生存期呈正相关，在训练集和验证集中均如此。此外，β-1,4-半乳糖基转移酶II的表达被确定为非转移性透明细胞肾细胞癌患者总生存期和无复发生存期的独立不良预后因素。最终，将β-1,4-半乳糖基转移酶II与其他独立预后参数相结合的列线图对于非转移性透明细胞肾细胞癌患者的总生存期和无复发生存期的预后准确性有显著提高。综上所述，β-1,4-半乳糖基转移酶II是术后复发和生存的潜在独立不良预后因素，通过一系列进一步的独立和回顾性研究，其可被开发成为非转移性透明细胞肾细胞癌的有用生物标志物，从而有助于透明细胞肾细胞癌患者的术后管理。
